Liquidity & Technical

Liquidity & Technical

DDL's NYSE ADS is structurally illiquid for institutional capital — at 20% participation in 20-day average dollar volume, a fund clears roughly ¥6.3M (about US$0.93M) over five trading sessions, which is well below the threshold needed to build any meaningful issuer-level position in normal market hours. The tape itself is mildly constructive: price sits 7.3% above the 200-day moving average after a January 2026 golden cross, but a string of failed rallies through the 50-day and a 12.7% three-month drawdown leave the short-term trend rolling over.

Note: DDL trades as a USD-denominated ADS on NYSE; values below are translated to CNY at the latest available FX rate (¥6.78 per US$1.00, 2026-05-26) for native-currency presentation. Price levels and chart shapes match the USD tape one-for-one.

Price Snapshot

Beta is a market-convention estimate for China consumer ADRs; not derived from the price tape directly.

Critical Chart — Five-Year Price & 50/200 SMA

Price is above the 200-day by 7.3% after the third golden cross of the post-IPO era (2026-01-14), but already below the 50-day, 100-day, and 20-day — classic pullback inside a young uptrend, with the burden of proof still on the bulls.

The full-history shape is a roughly 93% drawdown from the June 2021 IPO peak (¥259.83 / US$38.30 ADS-equivalent) into the January 2024 low (¥8.01 / US$1.18), followed by a base-building phase through 2024 and a sharp recovery rally peaking in October 2024 on China-consumer reflation flows. The current setup is the second test of that 2025-04 high.

Relative Performance — DDL Rebased

Benchmark (SPY) and sector overlays for this run did not compile a comparable series — the relative-performance file contains only the company line. DDL's standalone rebased path shows the stock down 19% over the trailing three years versus an SPY total return materially positive over that span, so the implied relative underperformance is sharp. Treat the absolute path as the read until benchmark data is rebuilt.

Momentum — RSI(14) and MACD Histogram

RSI sits at 47 — dead-neutral, neither oversold nor overbought, and has been mean-reverting around 45 since the December 2025 rally peaked at an extreme 83 reading. MACD histogram just flicked positive (+0.005) for the first time since early April, but the signal line is still below zero — short-term momentum is trying to turn, not confirmed.

Volume, Volatility, and Sponsorship

The 50-day average volume blew out from ~450K shares in April to a peak above 2.9M in late February on the post-rally washout, then collapsed back to ~450K shares — i.e., the December-January speculative interest left as fast as it arrived. With underlying daily participation back to the pre-rally baseline, the recent advance is not being confirmed by sponsorship.

Realized vol has collapsed to 25.7% — below the 10-year p20 reading of 54% and the lowest print in the dataset. The IPO-era peak topped 247% in April 2022. The current calm could mean either healthy base-building or a powder-keg setup ahead of the next catalyst — historically, multi-month sub-30% prints in this name have not lasted long.

Institutional Liquidity Panel

A. ADV & Turnover Strip

Note the disconnect: annual turnover at 117% suggests the float churns over once a year — if you're a retail-sized account. ADV at 0.16% of market cap is the institutional read, and it's three-to-five-times below what most funds need to size a position cleanly.

B. Fund-Capacity Table

The largest 5-day position at 20% ADV clears about ¥6.3M — so a fund with ¥126.7M in AUM (~US$18.7M) can build a 5% position in a week. A ¥316.9M (US$46.7M) fund needs to size at 2%. Anything above ¥1B AUM cannot make this a portfolio-relevant holding without weeks of patient execution.

C. Liquidation Runway Table

A 1% issuer-level position takes a full month to liquidate at aggressive 20% participation, six weeks at the more sustainable 10% rate. A 2% position is a quarter of patient block work. Anyone holding above 1% mcap is implicitly committed to the name — there is no quick exit.

D. Price-Range Proxy

Median 60-day daily range is 1.50%, below the 2% elevated-impact threshold. Intraday spreads and impact look benign on a per-share basis, but the daily notional available (¥6.3M / US$0.93M at 20% participation) is the binding constraint. Tight spreads on a tiny ADV is the classic illiquid-name profile.

Bottom line on capacity: the largest 5-day clearable position at 20% ADV is effectively 0.0% of market cap (literally rounded to zero on issuer-level percent), and even the most patient 10% participant clears nothing more than 0.08% in a week. This is a specialist or family-office name, not a fund-of-funds holding.

Technical Scorecard + Stance

Total: −2 of 6 — mildly bearish on a 3-to-6 month horizon. The January 2026 golden cross is the only thing holding this technical view above neutral; everything else is rolling over with the most recent rally already three months and 15% of price behind us. The structural read: liquidity is the constraint, full stop. Even a constructive setup wouldn't be actionable for any fund above mid-single-digit US$M AUM trying to size it cleanly. For institutional capital, the correct action is avoid or watchlist only; for specialist / sub-100MM funds with patient execution, the trade is to wait for a reclaim of ¥19.13 (50-day, equivalent to US$2.82 ADS) to add and stop on a daily close below ¥16.14 (200-day, equivalent to US$2.38 ADS), which would invalidate the post-golden-cross thesis.